HARVARD BIOSCIENCE develops, manufactures and markets tools used in drug discovery research at pharmaceutical and biotechnology companies, universities and government laboratories.
| Revenue (Most Recent Fiscal Year) | $94.14M |
| Net Income (Most Recent Fiscal Year) | $-12.40M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 0.37 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.29 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 7.16 |
| Pre-Tax Margin (Trailing 12 Months) | -61.34% |
| Net Margin (Trailing 12 Months) | -61.62% |
| Return on Equity (Trailing 12 Months) | -2.29% |
| Return on Assets (Trailing 12 Months) | -0.68% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.81 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.41 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 1.67 |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.45 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.22 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Common Shares Outstanding | 44.58M |
| Free Float | 40.34M |
| Market Capitalization | $32.23M |
| Average Volume (Last 20 Days) | 1.26M |
| Beta (Past 60 Months) | 1.53 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 9.50% |
| Percentage Held By Institutions (Latest 13F Reports) | 80.87% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |